Skip to main content
SpringerLink
Log in

Longitudinal assessment of the dose consistency of botulinum toxin type a (BOTOX®) for cervical dystonia

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Botulinum toxin type A (BoNT/A) is the principal therapy for patients with cervical dystonia. Repeated treatments over many years are required in most cases. This retrospective review evaluates the dose of BoNT/A used to treat cervical dystonia and the interval between treatments during a 2-year observation period. Outcomes data were abstracted from the medical records of 172 patients at 3 different sites who had received BoNT/A between January and December 1998. A total of 1059 treatments were assessed. Mean per-treatment doses throughout the 2-year study ranged from 241.80 to 254.07 units. The mean interval between treatments was 108.48 days during the first year of observation and 114.14 days during the second year. These findings indicate that doses of and intervals between BoNT/A treatments for cervical dystonia were consistent throughout 2 years of observation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jahanshahi M, Marion M.H, Marsden C.D. Natural history of adult-onset idiopathic torticollis.Arch Neurol. 1990;47:548–552.

    PubMed  CAS  Google Scholar 

  2. Dauer WT, Burke RE, Greene P, Fahn S. Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia.Brain. 1998;121(pt 4):547–560.

    Article  PubMed  Google Scholar 

  3. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections.Neurology. 1995;45:1743–1746.

    PubMed  CAS  Google Scholar 

  4. Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis.Lancet. 1986;2(8501):245–247.

    Article  PubMed  CAS  Google Scholar 

  5. Brans JW, Lindeboom R, Aramideh M, Speelman JD. Long-term effect of botulinum toxin on impairment and functional health in cervical dystonia.Neurology. 1998;50:1461–1463.

    PubMed  CAS  Google Scholar 

  6. Naumann M, Yakovleff A, Durif F. A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia.J Neurol. 2002;249:57–63.

    Article  PubMed  CAS  Google Scholar 

  7. Hilker R, Schischniaschvili M, Ghaemi M, Jacobs A, Rudolf J. Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia.J Neurol Neurosurg Psychiatry. 2001;71:193–199.

    Article  PubMed  CAS  Google Scholar 

  8. Brashear A, Watts MW, Marchetti A, Magar R, Lau H, Wang L. Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review.Clin Ther. 2000; 22:1516–1524.

    Article  PubMed  CAS  Google Scholar 

  9. Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up.Neurology. 1999;53:2102–2107.

    PubMed  CAS  Google Scholar 

  10. Mehta RP, Goldman SN, Orloff LA. Long-term therapy for spasmodic dysphonia: acoustic and aerodynamic outcomes.Arch Otolaryngol Head Neck Surg. 2001;127:393–399.

    PubMed  CAS  Google Scholar 

  11. Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period.Mov Disord. 2002;17:1288–1293.

    Article  PubMed  Google Scholar 

  12. Defazio G, Abbruzzese G, Girlanda P, et al. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study.Arch Neurol. 2002;59:418–420.

    Article  PubMed  Google Scholar 

  13. Jankovic J, Schwartz KS. Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia.Neurology. 1993;43:834–836.

    PubMed  CAS  Google Scholar 

  14. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis.Mov Disord. 1994;9:213–217.

    Article  PubMed  CAS  Google Scholar 

  15. BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex prescribing information. Allergan, Inc, Irvine, Calif, 2000.

    Google Scholar 

  16. Jankovic J, Ahsan J, Vuong KD. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia.Neurology. 2003;60:1186–1188.

    PubMed  CAS  Google Scholar 

  17. Dressler D, Munchau A, Bhatia KP, Quinn NP, Bigalke H. Antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses?Eur Neurol. 2002;47: 118–121.

    Article  PubMed  CAS  Google Scholar 

  18. Dutton JJ, Buckley EG. Long-term results and complications of botulinum A toxin in the treatment of blepharospasm.Ophthalmology. 1988;95:1529–1534.

    PubMed  CAS  Google Scholar 

  19. Dodel RC, Kirchner A, Koehne-Volland R, et al. Costs of treating dystonias and hemifacial spasm with botulinum toxin A.Pharmacoeconomics. 1997;12:695–706.

    Article  PubMed  CAS  Google Scholar 

  20. Hauser RA, Comella C, Brashear A, et al. A randomized, multicenter, double-blind, placebo-controlled study of original Botox (botulinum toxin type A) purified neurotoxin complex for the treatment of cervical dystonia [abstract].Mov Disord. 2000;15(suppl 2):30–31.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Indiana University Medical Center, 550 University Boulevard, Room 6620, 46202, Indianapolis, IN

    Allison Brashear MD

  2. Puget Sound Movement Disorder and Headache Clinic, Tacoma, Washington

    Patrick Hogan

  3. Neurology Specialists of Dallas, Dallas, Texas

    Maureen Wooten-Watts

  4. Thomson Health Economics Research, Secaucus, New Jersey

    Albert Marchetti, Raf Magar & John Martin

Authors
  1. Allison Brashear MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrick Hogan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maureen Wooten-Watts
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Albert Marchetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Raf Magar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. John Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brashear, A., Hogan, P., Wooten-Watts, M. et al. Longitudinal assessment of the dose consistency of botulinum toxin type a (BOTOX®) for cervical dystonia. Adv Therapy 22, 49–55 (2005). https://doi.org/10.1007/BF02850184

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02850184

Keywords

Search

Navigation